A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

← catalyst calendar

NCT07214571 · readout in 133 d

Sponsored by Shionogi (industry) · 4507.T — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

192estimated

Sites

Countries

Argentina, Bulgaria, Japan +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-12-11

actual

When the study began enrolling

Primary completion

2026-12-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-12-30

estimated

The whole study's end, after follow-up

First posted

2025-10-09

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-11

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Respiratory Syncytial Virus Infections

Interventions

Drug: S-337395
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Change From Baseline in RSV Ribonucleic Acid (RNA) Load by Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) (Nasopharyngeal Swab) at Day 2

measured Baseline, Day 2

Change From Baseline in RSV RNA Load by qRT-PCR (Nasopharyngeal Swab) at Day 4

measured Baseline, Day 4

Change From Baseline in RSV RNA Load by qRT-PCR (Nasopharyngeal Swab) at Day 6

measured Baseline, Day 6

Permalink · 4507.T's whole pipeline · Catalyst calendar · Every registered study · What changed